Wendy Diller

Senior Writer/Market Analyst

20 Years of Experience

About

Wendy writes on the medical devices and clinical diagnostics sectors, where she focuses on orthopedics/spine, molecular diagnostics and personalized medicine, clinical genomics, womens’ health/ femtech, and reimbursement/commercial strategy and innovation related to these specialties. She welcomes and encourages ideas and input from members of the MedTech Strategist Community.

Her career spans more than 20+ years as a top writer and manager focused on qualitative analysis of the global life sciences industry. She is Chair of Young Women in Bio Metro NY, an organization devoted to encouraging secondary students in the NY area to pursuit STEM careers and on the board of the Columbia Business School of Alumni Club NY

Articles from Wendy Diller:

Providers & Payors

In a Post-Inpatient Only Rule World, Tight ASC Margins, More Surgeon Choice

MS has eliminated all orthopedic procedures from the inpatient-only rule, as of January 1, 2026—part of a three-year plan to remove the list entirely--and is working on other policy changes that expand access to lower-cost ambulatory surgery centers. Experts highlight how these changes will affect manufacturers’ commercial strategies and influence ASC procurement in ways that both incentivize and discourage adoption of high-cost technologies.

Read Article